Key stats
About Tema Heart & Health ETF
Home page
Inception date
Nov 21, 2023
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Tema ETFs LLC
Distributor
Foreside Fund Services LLC
ISIN
US87975E8839
HRTS seeks long-term capital growth by targeting 15 to 100 pure-play companies at the forefront of combating diabetes, obesity, and cardiovascular diseases. This includes companies engaged in pharmaceuticals, emerging biotech, medical devices, and healthcare service providers. The fund aims to identify growth opportunities within the thematic universe, employing a dual-pronged approach involving top-down fundamental sector research and quantitative tools, as well as bottom-up security analysis. As part of the strategy, ESG factors are integrated to maximize returns and control risks. It utilizes a thorough analysis approach that combines internal research, external resources, and thematic strategies to pinpoint attractive investment opportunities. While holdings may include global stocks, a significant portion is expected to be directed toward the US and Europe. The fund may enter lending transactions.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.34%
Health Technology92.60%
Health Services4.94%
Distribution Services1.80%
Bonds, Cash & Other0.66%
Mutual fund0.53%
Cash0.13%
Stock breakdown by region
North America76.77%
Europe21.32%
Asia1.91%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
HRTS invests in stocks. The fund's major sectors are Health Technology, with 92.60% stocks, and Health Services, with 4.94% of the basket. The assets are mostly located in the North America region.
HRTS top holdings are Eli Lilly and Company and UnitedHealth Group Incorporated, occupying 8.05% and 4.94% of the portfolio correspondingly.
HRTS last dividends amounted to 0.14 USD. The year before, the issuer paid 0.33 USD in dividends, which shows a 128.41% decrease.
HRTS assets under management is 48.68 M USD. It's fallen 2.56% over the last month.
HRTS fund flows account for −28.32 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, HRTS pays dividends to its holders with the dividend yield of 0.47%. The last dividend (Dec 12, 2024) amounted to 0.47 USD. The dividends are paid annually.
HRTS shares are issued by Dawn Global Topco Ltd. under the brand Tema. The ETF was launched on Nov 21, 2023, and its management style is Active.
HRTS expense ratio is 0.75% meaning you'd have to pay 0.75% of your investment to help manage the fund.
HRTS follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
HRTS invests in stocks.
HRTS price has risen by 3.22% over the last month, and its yearly performance shows a −12.33% decrease. See more dynamics on HRTS price chart.
NAV returns, another gauge of an ETF dynamics, showed a 8.55% increase in three-month performance and has decreased by −10.19% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 8.55% increase in three-month performance and has decreased by −10.19% in a year.
HRTS trades at a premium (0.06%) meaning the ETF is trading at a higher price than the calculated NAV.